Dextromethorphan Shows Promise for Treating Lung Fibrosis in Study

December 23, 2024

Lung fibrosis, or pulmonary fibrosis, is a debilitating disease characterized by the excessive buildup of fibrillar collagen, leading to scarring in the lung tissue. This scarring makes lung tissues stiff and reduces their elasticity, resulting in severe breathing difficulties and decreased oxygen levels in the bloodstream. If left unaddressed, lung fibrosis can ultimately lead to organ failure. The condition is especially prevalent among older adults and can be triggered by various factors, including exposure to environmental irritants, side effects from cancer chemotherapy, serious lung infections, and autoimmune diseases.

The Discovery of Dextromethorphan’s Potential

Initial Research and Motivation

The driving force behind this research was the absence of an effective cure for lung fibrosis. Developing new drugs is a significant challenge, both in terms of time and resources. This directed scientists towards exploring FDA-approved drugs that might have untapped potential. During a screening of a library of FDA-approved drugs for possible anti-fibrotic effects, dextromethorphan was identified. With the extensive use of dextromethorphan in over-the-counter cough syrups, its safety profile was well-established, which accelerated the interest in its potential repurposing.

Muzamil Majid Khan, the paper’s first author and an EMBL research associate, emphasized the necessity of finding a viable treatment rapidly due to the progressive and often fatal nature of lung fibrosis. The research team aimed to identify drugs that could reduce the fibrotic process by targeting the pathways involved in excessive collagen deposition. Dextromethorphan emerged as a candidate due to its previously unknown effects on collagen production and deposition within lung tissue. The identification of this drug provided a promising avenue for further investigation.

Collaborative Efforts and Advanced Techniques

In collaboration with the Translational Lung Research Center (TLRC) Heidelberg and the German Center for Lung Research (DZL), the EMBL team worked with human lung cells using advanced and innovative technologies. The research employed a high-throughput microscopy technique and an advanced ‘scar-in-a-jar’ assay system, used to simulate lung fibrosis in vitro by replicating the full process of collagen deposition. This simulation allowed scientists to test the efficacy of various anti-fibrotic drugs effectively. The ‘scar-in-a-jar’ model was pivotal in understanding how dextromethorphan could influence the molecular mechanisms of collagen buildup.

Using high-throughput microscopy, researchers could observe cellular changes in response to dextromethorphan treatment, thereby gaining a clearer understanding of its anti-fibrotic properties. This innovative approach enabled the team to screen numerous drug candidates quickly, identifying dextromethorphan’s unique potential. Collaborative efforts also involved employing state-of-the-art imaging techniques and biochemical assays to elucidate the pathways modulated by dextromethorphan during the fibrotic process. These advanced techniques brought a new level of precision and insight to the study, underscoring the importance of interdisciplinary collaboration in medical research.

Preclinical Testing and Results

Testing in Mouse Models

The findings from the early stages of research led to testing dextromethorphan in mouse models of lung fibrosis. The results indicated that dextromethorphan significantly reduced the accumulation of collagen, essentially ameliorating lung fibrosis by impeding collagen trafficking within the cells. This reduction in collagen levels directly correlated with improved lung function in the treated mice. By alleviating fibrosis, the drug helped maintain the elasticity and function of the lung tissue, which is crucial for effective respiratory activity.

Examining the lung tissues of the treated mouse models, researchers observed a marked decrease in the markers associated with fibrosis, which are typically elevated in diseased states. This substantial reduction in fibrotic markers suggested that dextromethorphan might inhibit or slow the progression of fibrosis. These promising results in animal models were compelling enough to justify moving forward with more complex and human-relevant experimental setups. The positive outcomes in these preclinical tests provided a robust foundation for further exploration of dextromethorphan’s therapeutic potential.

Human Lung Tissue Cultures

Further testing was conducted in live 3D organotypic human lung tissue cultured in the laboratory. The results mirrored those seen in the mouse models, showing a significant reduction in collagen accumulation. This promising discovery has piqued interest and led to the planning of Phase II clinical trials in collaboration with the Thoraxclinic in Heidelberg. The live 3D organotypic models provided a more accurate representation of human lung physiology, offering crucial insights into how dextromethorphan may function in human patients.

The cultured human lung tissues allowed researchers to observe the drug’s effects in a controlled environment that closely mimics the in vivo conditions of lung fibrosis. This setup enabled the team to monitor cellular responses and assess the drug’s effectiveness over time. The reduction in collagen accumulation in these tissues indicated that dextromethorphan might exert its beneficial effects by modulating specific cellular pathways involved in fibrosis. This preclinical success demonstrated the drug’s potential to improve current treatment options for patients suffering from lung fibrosis.

Future Directions and Clinical Trials

Phase II Clinical Trials

The upcoming Phase II clinical trials aim to assess whether the beneficial effects observed in preclinical models translate into positive outcomes in human patients with lung fibrosis. These trials will be crucial in confirming the drug’s efficacy in humans and could potentially herald a significant breakthrough in the management of pulmonary fibrosis. The primary goals of these trials include evaluating the safety and tolerability of dextromethorphan in lung fibrosis patients while measuring its impact on key markers of fibrosis and overall lung function.

Success in these trials would represent a significant step forward, potentially leading to the fast-tracking of dextromethorphan for wider clinical use. Patients enrolled in these trials will undergo rigorous monitoring to ensure accurate data collection, thereby allowing researchers to make informed decisions regarding the drug’s efficacy and optimal dosage. Positive outcomes could also pave the way for larger-scale clinical trials, eventually leading to the drug’s approval for treating lung fibrosis.

Understanding Mechanisms and Optimizing Treatment

Future investigations will delve deeper into understanding the mechanisms by which dextromethorphan works, identifying the specific molecular targets in cells relevant to the disease. This thorough understanding may pave the way for developing improved variants of the drug, optimizing its efficacy in treating lung fibrosis. Researchers aim to isolate the precise pathways through which dextromethorphan exerts its anti-fibrotic effects, potentially unveiling new targets for intervention.

Through detailed molecular studies, scientists hope to uncover the exact processes that dextromethorphan influences at a cellular level. This knowledge could lead to the development of more effective treatment regimens or the combination of dextromethorphan with other therapies to enhance its therapeutic impact. Ultimately, the goal is to offer patients a more potent and reliable treatment option by leveraging the detailed insights gained from these ongoing investigations.

Support and Implications

Collaborative Support

The study received valuable support from EMBL’s Proteomic Core facility, Chemcore, and medicinal chemists. This interdisciplinary collaboration and the use of advanced scientific techniques have been instrumental in uncovering new roles for established medications. The collaborative environment at EMBL facilitated the integration of diverse expertise, ranging from cell biology to pharmacology, essential for comprehensive understanding and advancement in this research field.

By pooling resources and knowledge, the researchers were able to address the complex challenge of lung fibrosis more effectively. The involvement of multiple core facilities and expertise allowed for a multi-faceted approach to the problem, ensuring that all aspects of the drug’s impact were thoroughly examined. This kind of broad-based support is crucial for translating basic scientific discoveries into clinical applications that can significantly benefit patients.

Implications for Drug Repurposing

The success of the dextromethorphan study underscores the potential for repurposing existing drugs to treat other serious conditions. Drug repurposing offers a faster and often more cost-effective path to new therapies by leveraging established safety profiles and manufacturing processes. This approach can be particularly valuable in addressing diseases with limited treatment options, such as lung fibrosis. The findings from this research may inspire further investigations into other approved drugs with unexplored therapeutic benefits, potentially leading to innovative treatments for various ailments. The overarching implication is that the vast library of existing medications holds untapped potential that, with the right scientific inquiry, can be harnessed to improve patient outcomes and advance medical science.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later